AIM Highlights Ampligen Potential in Pancreatic Cancer
OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...
Orphan Drug
Advertisement
Ophirex Publishes Phase 2 BRAVIO Varespladib Data
Durham, North Carolina — September 22, 2026 Ophirex announced publication of results from the Phase 2 BRAVIO clinical trial...
Arcturus to Present ARCT-810 Phase 2 OTC Deficiency Data
SAN DIEGO — September 18, 2026 Arcturus Therapeutics announced plans to provide an update on its ARCT-810 Phase 2...
Beacon Therapeutics Reports Positive VISTA Data for Laru-zova
LONDON and CAMBRIDGE, Mass September 21, 2026 — Beacon Therapeutics announced positive topline results from the pivotal VISTA trial...
Abbisko Therapeutics Reports Positive Phase 2 Lavengratinib Data
Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...
Advertisements
MaaT Pharma Advances PHOENIX After Negative EMA Opinion
LYON, France — September 18, 2026 MaaT Pharma announced that the Committee for Medicinal Products for Human Use (CHMP)...
One04 Therapeutics Launches With CPV-104 Clinical Expansion
FREIBURG, Germany — September 15, 2026 One04 Therapeutics GmbH & Co. KG announced its launch as a clinical-stage biopharmaceutical...
Tenaya Therapeutics Gains RMAT Designation for TN-401
SOUTH SAN FRANCISCO, Calif. — September 14, 2026 Tenaya Therapeutics, Inc. announced that the U.S. Food and Drug Administration...
Lundbeck Gains FDA Orphan Drug Status for Asedebart
Copenhagen, Denmark, September 10, 2026 H. Lundbeck A/S has announced that the U.S. Food and Drug Administration (FDA) has...
Can-Fite Reports Namodenoson Liver Cirrhosis Case
RAMAT GAN, Israel — September 9, 2026 Can-Fite BioPharma Ltd. announced publication of a peer-reviewed case report describing clinical...
Advertisement
